Sucampo Receives $15M Milestone Payment from Abbott for AMITIZA

Loading...
Loading...
Sucampo Pharmaceuticals.
SCMP
today announced that its subsidiary, Sucampo AG, has received a $15 million milestone payment from Abbott's
ABT
subsidiary, Abbott Japan Co., Ltd. (Abbott), pursuant to the existing license, commercialization, and supply agreement between Sucampo Pharma Ltd. (SPL), SPI's subsidiary, and Abbott. The milestone payment was triggered by the first sale of AMITIZA® (lubiprostone) capsule 24 μg in Japan. AMITIZA is available through Abbott in Japan as a prescription medication for chronic constipation not caused by organic diseases, and was launched to primary care and specialist physicians on November 21, 2012. “For years, millions of patients in Japan have been suffering from chronic constipation,” said Sucampo's Chairman,
See full press release
Posted In: NewsGuidanceContractsManagementGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...